PT  - JOURNAL ARTICLE
AU  - Sheersha Pramanik
AU  - Sucheta Karmakar
AU  - Shreyas Mukherjee
AU  - Indraneel Dhavale
AU  - Rohan Shrestha
TI  - Unmasking the Current Scenario of Indian Biomedical Devices Industry: Ventilators being the Heart of the Discussion
AID  - 10.1101/2021.02.26.21251720
DP  - 2021 Jan 01
TA  - medRxiv
PG  - 2021.02.26.21251720
4099  - http://medrxiv.org/content/early/2021/03/02/2021.02.26.21251720.short
4100  - http://medrxiv.org/content/early/2021/03/02/2021.02.26.21251720.full
AB  - Background The Indian Biomedical Device Industry has been growing at an unprecedented rate, but several hindrances need to be acknowledged in offering access to quality, budget-friendly medical devices in India. This article explores the current loopholes of the Indian biomedical device industry along with the proposal of various innovative solutions, with emphasis on ventilators.Methods An online survey with the help of Google forms was conducted from 1st November to 25th December 2020, addressing the problems of the Indian medical device industry (MDI) along with probable solutions. The survey also provides a glimpse into the complications aroused from the frequent use of ventilators during COVID-19 outburst, along with possible measures.Results According to the survey, 51.6%, 46.5%, 55.7%, and 47.5% of respondents have agreed to ‘Stringent laws and implementation,’ ‘Safety testing and strict regulations,’ ‘Unfavorable duty structure,’ and ‘Reducing tax rate on domestic manufacturers,’ as a possible solution to advance the implementation of ISO 13485 and ISO 10651, implementation of ISO 14971, the probable cause of limitations of Indian MDI, possible measure to overcome limitations of Indian MDI, respectively. 46.7%, 47.5%, 46.2%, and 44.6% of respondents have agreed to ‘Surgical decompression,’ ‘Nebulized and broad-spectrum antibiotics,’ ‘PEEP,’ and ‘Adopting lung protective ventilation strategies’ as possible solutions to treat various ventilator complications, respectively.Conclusion The study briefs about the people’s perception of the Indian MDI as well as on the ventilator complications. The results complied with our hypothesis as the majority of the respondents have agreed with almost all the probable solutions in both the sections given by us as options.Competing Interest StatementThe authors have declared no competing interest.Funding StatementNoneAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This study was exempted by the Indian Pharmacy Graduates' Association (Reg id: S/8255 of 1976) Ethics committee members: a) Mr. Atul Nasa, President, IPGA, Managing Trustee, IPGA Welfare Trust Deputy drugs controller with the charge of Controlling & Licensing Authority (CLA) at the drugs control department in Delhi government. b) Dr. Arun Garg, General Secretary, IPGA Dean, Institute of Pharmacy, NIMS University, Rajasthan c) Dr. Vijay Bhalla, Treasurer, IPGA Dean, SGT College of Pharmacy, SGT University, Haryana All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData available within the article or its supplementary materialsMDIMedical devices industrySARS-CoV-2Severe acute respiratory syndrome coronavirus 2 FDA-Food and Drug AdministrationEUEuropean UnionCEConformité EuropéenneCOVID-19Coronavirus disease 2019ISOInternational Organization for Standardization IT-Information TechnologyIITIndian Institutes of TechnologyARDSAcute respiratory distress syndrome CT-Computed tomographyMDRMedical Device ReportingEMAEuropean Medicines Agency US-United StatesQMSQuality management system Govt. – GovernmentDCGIDrugs Controller General of India CL-Compulsory LicensingUSFDAUnited States Food and Drug Administration COPD-Chronic Obstructive Pulmonary DiseaseILDInterstitial Lung DiseaseARDSAcute Respiratory Distress Syndrome AI-Artificial IntelligenceVAPVentilator-Associated Pneumonia ET-Endo-Tracheal TubeICUIntensive Care UnitSSDSubglottic Secretion Drainage MDR-Multi-Drug ResistantPEEPPositive End-Expiratory Pressure PVC-Poly Vinyl ChlorideMVMechanical VentilationVLIVentilator-Induced Lung InjuryNMBANeuro-Muscular Blocking Agents RR-Respiratory RegulationECMOExtra-Corporeal Membrane Oxygenation PP-Prone Positioning